Navigation Links
PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
Date:8/28/2007

iatives.

Based primarily on its strategic shift to focus on discovery and development of antibodies in oncology and select immunological diseases, PDL is conducting a thorough review of its organization, and anticipates a sizeable workforce reduction, to ensure that its structure and scope of operations are appropriately aligned with the new strategy.

Planned Sale of Commercial Operations

Given the change in strategic direction of the company and current timing of its pipeline, the company has determined that its commercial products and cardiovascular development programs are no longer a strategic fit.

As a result, the company has engaged Merrill Lynch & Co. to advise it on the sale of the rights to Cardene, Retavase, IV Busulfex and ularitide, and related assets, in one or more transactions. The company is seeking to retain staff in approximately 250 positions that support its commercial and cardiovascular products through the completion of the planned sale(s), but expects to eliminate these positions in connection with the sales of the company's commercial assets, which would be in addition to the workforce reduction anticipated in connection with aligning the organization to the company's new strategy. PDL has not finalized its plans for the optimal use of proceeds from the sale of these assets, but will provide updates on these and other financial options at the appropriate time. The company anticipates that its earnings will be significantly reduced in the near term following the sale of the marketed products, which generated $187.2 million in revenues in the 12 months ended June 30, 2007. Given the uncertain timing of and charges related to the planned transaction(s) and overall realignment, the company has suspended its financial guidance for 2007.

"Our marketed products have been an important component of the financial value of PDL, but they simply no longer fit with our new direction and timeline for commercialization of our in
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Many factors impact tissues targeting such as protein ... the blood-tissue barrier. Even when tissue disposition is achieved, ... tissue rather than the total tissue concentration. , A ... guide lead optimization, predict in vivo activity in animal ... impact the likely human clinical dose. , In this ...
(Date:5/24/2013)... May 24, 2013 Vestiage, Inc. ... company focused on science-based research and development, sales ... cosmeceuticals and nutraceuticals, announced today that it is ... for the sale of Reluma Skin Illuminating Facial ... and application by sending an email to info(at)vestiageinc(dot)com ...
(Date:5/23/2013)... CAMBRIDGE, England , May 24, 2013 ... von Mundipharma angefertigt – Bei der ... Version , 91 % der Teilnehmer einer ... obwohl nur 20 % laut GINA [*] -Definition [1] ... zeigt, dass Menschen mit Asthma generell einer von vier ...
(Date:5/23/2013)... 23, 2013 Venaxis, Inc. (Nasdaq:   APPY), ... obtaining FDA clearance and commercializing its rapid, protein biomarker-based ... of an underwritten public offering of 10,000,000 shares of ... shares of its common stock at an exercise price ... price of $1.25 per share and related warrant.  Venaxis ...
Breaking Biology Technology:DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... other states jockeyed for position on Business Facilities ... ranking as best in the Midwest and No. 4 ... bioscience industry . , (Logo: ... ranking is in part due to updated estimates of ...
... iPierian, Inc., a biopharmaceutical company focused on changing the ... of cellular reprogramming, today announced that it has been ... of Health (NIH) Grand Opportunities (GO) grant awarded to ... two-year span, will be used to generate amyotrophic lateral ...
... Inc. (Nasdaq CM: CRTX), a specialty pharmaceutical company focused ... the respiratory and related markets, today announced that it ... on Wednesday, November 4, 2009, to discuss its financial ... Management will also provide an update on the Company,s ...
Cached Biology Technology:Ohio Bioscience Industry Leads Midwest, Among Best in Nation as Investment Destination 2iPierian to Collaborate With Johns Hopkins University on $3.7 Million NIH Grand Opportunities Grant 2Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call 2Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call 3
(Date:5/23/2013)... the interplay of brain chemicals which help us pay ... BBSRC. , By changing the way neurons respond ... these changes can affect the strength of a neuronal ... response. , Lead author Alex Thiele, Professor ... you can make yourself better heard by speaking louder ...
(Date:5/22/2013)... to improve durability in fuel cell powered buses, ... discovered links between electrode degradation processes and bus ... effects of electrode degradation stressors in the operating ... , The findings of the study, led by ... in a long-term study at Burnaby-based Ballard Power ...
(Date:5/22/2013)... engineering drastically reduces the time and effort needed ... of biotechnology, scientists are reporting. Published in the ... paves the way for more rapid development of ... other activities. , Keith Shearwin and colleagues explain ... genetic material DNA into a bacterium,s genome is ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2
... is the champion of all gliding mammals, able to ... length of two football fields, execute 90-degree turns and ... in Singapore, the United Kingdom and at the University ... with the help of a miniature backpack outfitted with ...
... availability of new genome sequencing technology has prompted ... intriguing hypothesis about how agricultures early beginnings may ... Boris Vinatzer, assistant professor of plant pathology, physiology, ... and Life Sciences, has received a $1 million, ...
... YORK (FEBRUARY 7, 2008) Madagascars turtles and tortoises, ... will continue to crawl steadily toward extinction unless major ... by the Wildlife Conservation Society and other groups. ... capital city Antananarivo, said there is still hope to ...
Cached Biology News:Accelerometer backpacks aid study of gliding behavior in the 'flying' lemur 2Accelerometer backpacks aid study of gliding behavior in the 'flying' lemur 3Tomato pathogen genome may offer clues about bacterial evolution at dawn of agriculture 2Madagascar's tortoises are crawling toward extinction, groups say 2
Request Info...
... 0 (or Cap 0-like) RNA into Cap ... been shown to increase in vivo translation ... is seen in Cap 0 structures created ... well as those Cap 0 structures created ...
Form: Ready to use Applications: ELISA...
RABBIT ANTI HALOPERIDOL...
Biology Products: